Loading
Brain Cancer / Targeted Therapy · Journal article
Future Science Oa · August 10, 2026
A consensus or society position rather than new primary data.
This is a narrative review of glioblastoma molecular biology and therapeutic resistance mechanisms. It identifies gaps in clinical translation of preclinical findings—specifically compensatory signaling, blood-brain barrier penetration, and tumor heterogeneity—and recommends biomarker stratification, improved CNS delivery, and combination therapy as future directions, without reporting new clinical evidence or trial outcomes.
Narrative review. Patients with glioblastoma (inferred from title and context; not explicitly stated in excerpt)..
Many pathway-directed treatments show promising preclinical activity but clinical translation remains challenging Treatment resistance is mediated by compensatory signaling, blood-brain barrier limitations, and molecular heterogeneity Future progress depends on biomarker-driven stratification, improved CNS drug delivery, and rational combination therapies
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and researchers should recognize that preclinical glioblastoma drug activity does not reliably predict clinical benefit, and consider multi-targeted combination approaches with biomarker selection and improved CNS penetration as priorities for future trial design.
A narrative review synthesizing molecular mechanisms of glioblastoma resistance and recommending future therapeutic strategies, without new empirical data or clinical trial results.
As stated by the source record.
Clinicians and researchers should recognize that preclinical glioblastoma drug activity does not reliably predict clinical benefit, and consider multi-targeted combination approaches with biomarker selection and improved CNS penetration as priorities for future trial design.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Results. The review further examines mechanisms underlying treatment resistance and the limitations of current targeted therapies. Although many pathway-directed treatments have demonstrated promising preclinical activity, clinical translation remains challenging because of compensatory signaling, blood-brain barrier limitations, and molecular heterogeneity.Conclusion: Future progress will likely depend on biomarker-driven patient stratification, improved CNS drug delivery, and rational combination therapies capable of simultaneously targeting multiple tumor-promoting mechanisms.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.